Surface Oncology Inc (NASDAQ:SURF) was the recipient of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 428,700 shares, a drop of 47.2% from the June 30th total of 811,700 shares. Based on an average daily trading volume, of 2,220,000 shares, the short-interest ratio is currently 0.2 days. Currently, 3.3% of the company’s stock are short sold.
Surface Oncology stock opened at $5.21 on Friday. Surface Oncology has a 1-year low of $1.15 and a 1-year high of $7.66. The business has a fifty day moving average price of $5.41 and a 200-day moving average price of $3.60. The company has a debt-to-equity ratio of 0.43, a current ratio of 6.97 and a quick ratio of 6.97.
Surface Oncology (NASDAQ:SURF) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.31. Surface Oncology had a negative net margin of 70.90% and a negative return on equity of 38.44%. The business had revenue of $38.59 million for the quarter, compared to analyst estimates of $38.59 million. Research analysts anticipate that Surface Oncology will post -0.96 EPS for the current fiscal year.
Several brokerages have issued reports on SURF. Cowen reiterated an “average” rating on shares of Surface Oncology in a report on Thursday, June 11th. Zacks Investment Research downgraded shares of Surface Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine downgraded Surface Oncology from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. Finally, Evercore ISI reiterated a “market perform” rating and issued a $9.00 target price on shares of Surface Oncology in a report on Monday, June 8th.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.
Featured Story: How does a dividend reinvestment plan work?
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.